Silco Pharmaceuticals Limited
  • Home
  • About Us
  • Products
    • Product Catalogue
  • Facilities
  • Investor
    • Notice
    • Annual Report & Audited Accounts
    • New Annual Report & Audited Accounts
    • Half Yearly Reports
    • Quarterly Reports
      • First Quarter Accounts ended Sep. 30, 2025
    • Price Sensitive Information (PSI)
    • Code of Conduct
    • Dividend Compliance Report
    • Dividend Disbursement Policy
    • Unpaid/Unclaimed Dividend
    • Prospectus
    • TT clean rate
    • Utilization Report
  • Global Operations
  • Contact Us
Select Page

Corporate Governance Code (CGC)

Revised Dividend Payment Compliance Report 2024-2025

Please click the Link Below to view the Report.

Revised Dividend Payment Compliance Report 2024-2025

Dividend Payment Compliance Report 2024-2025

Please click the Link Below to view the Report.

Dividend Payment Compliance Report 2024-2025

Registered & Head Office

Nurani-41, Ban-Kalapara, Subid Bazar, Sylhet-3100, Bangladesh.

Phone: +8802996638241

E-mail:  info@silcopharma.com

 

 

 

 

 

 

 

 

 

 

 

 

 

ABOUT US

  • Home
  • About Us
  • Products
    • Product Catalogue
  • Facilities
  • Investor
    • Notice
    • Annual Report & Audited Accounts
    • New Annual Report & Audited Accounts
    • Half Yearly Reports
    • Quarterly Reports
      • First Quarter Accounts ended Sep. 30, 2025
    • Price Sensitive Information (PSI)
    • Code of Conduct
    • Dividend Compliance Report
    • Dividend Disbursement Policy
    • Unpaid/Unclaimed Dividend
    • Prospectus
    • TT clean rate
    • Utilization Report
  • Global Operations
  • Contact Us

PRODUCTS

  • By Trade Name
  • By Generic Name
  • By Therapeutic Class

FACILITIES

  • Quality Policy
  • Manufacturing Facility
  • Quality Assurance
  • HVAC system
  • Cephalosporin Unit
  • Wastewater Treatment
  • Facebook
  • Twitter
  • Google
  • Youtube
  • RSS
© Silcopharma 2024 || Designed and Develop by Momi Technology LLC